Skip to main content

Table 2 Vaccine effectiveness against all-cause pneumonia, IPD and AOM

From: Cost-effectiveness evaluation of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine for children in Taiwan

Serotype PHiD-CV PCV13 References
All-cause pneumonia
 Inpatient 23.4% 23.7% [11]
 Outpatient 7.3% 7.3% (assumed to be the same as PHiD-CV) [11]
IPD
 VT (10 common ST) 94.7% 94.7% [28]
 3 0% 0% [32] [33]
 6A 76.0% (assumed to be the same as PCV7) 94.7% (VT) [28]
 19A 71% (base case)
19% (used in scenario analysis: worst case using Taiwan point estimate of PCV7/10)
80% [12, 13, 34]
AOM
 AOM VT VE 10 common serotypes 69.9% 69.9% [11]
 ST3 AOM VE 0% [10] 0% [11]
 6A AOM VE 29.0% 69.9% [11]
 19A 29.0% 69.9% [11]
 NVT AOM VE −33% −33% [35]
 NTHi AOM VE 21.5% [11] [0–35.3% in sensitivity analysis] 0% (based on expert opinion) [−11 to + 8% in sensitivity analysis] [11, 35, 36]
 AOM Myringotomy 50.92% 30.6% Estimated based on [37, 38] and overall AOM efficacies above
  1. AOM acute otitis media, IPD invasive pneumococcal disease, NTHi non-typeable Haemophilus Influenzae, NVT non-vaccine type, PCV7/13 7/13-valent pneumococcal conjugate vaccine, PHiD-CV 10-valent pneumococcal polysaccharide and NTHi protein D conjugate vaccine, ST serotype, VE vaccine effectiveness, VT vaccine-type
\